Plasma Derived Medicine Market Size, Share, Growth, and Industry Analysis, By Types (Albumin, Immune Globulin, Coagulation Factor, Others) , Applications (Bleeding Wound, Immunodeficiency, HBV, Tetanus, Rabies, Hemophilia, Others) and Regional Insights and Forecast to 2033

Detailed TOC of Global Plasma Derived Medicine Market Research Report 2025

1 Plasma Derived Medicine Market Overview
1.1 Product Overview and Scope of Plasma Derived Medicine
1.2 Plasma Derived Medicine Segment by Type
1.2.1 Global Plasma Derived Medicine Market Value Comparison by Type (2025-2033)
1.2.2 Albumin
1.2.3 Immune Globulin
1.2.4 Coagulation Factor
1.2.5 Others
1.3 Plasma Derived Medicine Segment by Application
1.3.1 Global Plasma Derived Medicine Market Value by Application: (2025-2033)
1.3.2 Bleeding Wound
1.3.3 Immunodeficiency
1.3.4 HBV
1.3.5 Tetanus
1.3.6 Rabies
1.3.7 Hemophilia
1.3.8 Others
1.4 Global Plasma Derived Medicine Market Size Estimates and Forecasts
1.4.1 Global Plasma Derived Medicine Revenue 2018-2033
1.4.2 Global Plasma Derived Medicine Sales 2018-2033
1.4.3 Global Plasma Derived Medicine Market Average Price (2018-2033)
1.5 Assumptions and Limitations
2 Plasma Derived Medicine Market Competition by Manufacturers
2.1 Global Plasma Derived Medicine Sales Market Share by Manufacturers (2018-2025)
2.2 Global Plasma Derived Medicine Revenue Market Share by Manufacturers (2018-2025)
2.3 Global Plasma Derived Medicine Average Price by Manufacturers (2018-2025)
2.4 Global Plasma Derived Medicine Industry Ranking 2021 VS 2022 VS 2025
2.5 Global Key Manufacturers of Plasma Derived Medicine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Plasma Derived Medicine, Product Type & Application
2.7 Plasma Derived Medicine Market Competitive Situation and Trends
2.7.1 Plasma Derived Medicine Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Plasma Derived Medicine Players Market Share by Revenue
2.7.3 Global Plasma Derived Medicine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Plasma Derived Medicine Retrospective Market Scenario by Region
3.1 Global Plasma Derived Medicine Market Size by Region: 2018 Versus 2022 Versus 2033
3.2 Global Plasma Derived Medicine Global Plasma Derived Medicine Sales by Region: 2018-2033
3.2.1 Global Plasma Derived Medicine Sales by Region: 2018-2025
3.2.2 Global Plasma Derived Medicine Sales by Region: 2024-2033
3.3 Global Plasma Derived Medicine Global Plasma Derived Medicine Revenue by Region: 2018-2033
3.3.1 Global Plasma Derived Medicine Revenue by Region: 2018-2025
3.3.2 Global Plasma Derived Medicine Revenue by Region: 2024-2033
3.4 North America Plasma Derived Medicine Market Facts & Figures by Country
3.4.1 North America Plasma Derived Medicine Market Size by Country: 2018 VS 2022 VS 2033
3.4.2 North America Plasma Derived Medicine Sales by Country (2018-2033)
3.4.3 North America Plasma Derived Medicine Revenue by Country (2018-2033)
3.4.4 United States
3.4.5 Canada
3.4.6 Mexico
3.5 Europe Plasma Derived Medicine Market Facts & Figures by Country
3.5.1 Europe Plasma Derived Medicine Market Size by Country: 2018 VS 2022 VS 2033
3.5.2 Europe Plasma Derived Medicine Sales by Country (2018-2033)
3.5.3 Europe Plasma Derived Medicine Revenue by Country (2018-2033)
3.5.4 Germany
3.5.5 France
3.5.6 UK
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Plasma Derived Medicine Market Facts & Figures by Country
3.6.1 Asia Pacific Plasma Derived Medicine Market Size by Country: 2018 VS 2022 VS 2033
3.6.2 Asia Pacific Plasma Derived Medicine Sales by Country (2018-2033)
3.6.3 Asia Pacific Plasma Derived Medicine Revenue by Country (2018-2033)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Indonesia
3.6.10 Thailand
3.6.11 Malaysia
3.6.12 Philippines
3.6.13 Vietnam
3.7 Latin America Plasma Derived Medicine Market Facts & Figures by Country
3.7.1 Latin America Plasma Derived Medicine Market Size by Country: 2018 VS 2022 VS 2033
3.7.2 Latin America Plasma Derived Medicine Sales by Country (2018-2033)
3.7.3 Latin America Plasma Derived Medicine Revenue by Country (2018-2033)
3.7.4 Brazil
3.8 Middle East and Africa Plasma Derived Medicine Market Facts & Figures by Country
3.8.1 Middle East and Africa Plasma Derived Medicine Market Size by Country: 2018 VS 2022 VS 2033
3.8.2 Middle East and Africa Plasma Derived Medicine Sales by Country (2018-2033)
3.8.3 Middle East and Africa Plasma Derived Medicine Revenue by Country (2018-2033)
3.8.4 Turkey
3.8.5 GCC Countries
3.8.6 Egypt
3.8.7 South Africa
4 Segment by Type
4.1 Global Plasma Derived Medicine Sales by Type (2018-2033)
4.1.1 Global Plasma Derived Medicine Sales by Type (2018-2025)
4.1.2 Global Plasma Derived Medicine Sales by Type (2024-2033)
4.1.3 Global Plasma Derived Medicine Sales Market Share by Type (2018-2033)
4.2 Global Plasma Derived Medicine Revenue by Type (2018-2033)
4.2.1 Global Plasma Derived Medicine Revenue by Type (2018-2025)
4.2.2 Global Plasma Derived Medicine Revenue by Type (2024-2033)
4.2.3 Global Plasma Derived Medicine Revenue Market Share by Type (2018-2033)
4.3 Global Plasma Derived Medicine Price by Type (2018-2033)
5 Segment by Application
5.1 Global Plasma Derived Medicine Sales by Application (2018-2033)
5.1.1 Global Plasma Derived Medicine Sales by Application (2018-2025)
5.1.2 Global Plasma Derived Medicine Sales by Application (2024-2033)
5.1.3 Global Plasma Derived Medicine Sales Market Share by Application (2018-2033)
5.2 Global Plasma Derived Medicine Revenue by Application (2018-2033)
5.2.1 Global Plasma Derived Medicine Revenue by Application (2018-2025)
5.2.2 Global Plasma Derived Medicine Revenue by Application (2024-2033)
5.2.3 Global Plasma Derived Medicine Revenue Market Share by Application (2018-2033)
5.3 Global Plasma Derived Medicine Price by Application (2018-2033)
6 Key Companies Profiled
6.1 Takeda
6.1.1 Takeda Corporation Information
6.1.2 Takeda Description and Business Overview
6.1.3 Takeda Plasma Derived Medicine Sales, Revenue and Gross Margin (2018-2025)
6.1.4 Takeda Plasma Derived Medicine Product Portfolio
6.1.5 Takeda Recent Developments/Updates
6.2 CSL
6.2.1 CSL Corporation Information
6.2.2 CSL Description and Business Overview
6.2.3 CSL Plasma Derived Medicine Sales, Revenue and Gross Margin (2018-2025)
6.2.4 CSL Plasma Derived Medicine Product Portfolio
6.2.5 CSL Recent Developments/Updates
6.3 Grifols
6.3.1 Grifols Corporation Information
6.3.2 Grifols Description and Business Overview
6.3.3 Grifols Plasma Derived Medicine Sales, Revenue and Gross Margin (2018-2025)
6.3.4 Grifols Plasma Derived Medicine Product Portfolio
6.3.5 Grifols Recent Developments/Updates
6.4 Octapharma
6.4.1 Octapharma Corporation Information
6.4.2 Octapharma Description and Business Overview
6.4.3 Octapharma Plasma Derived Medicine Sales, Revenue and Gross Margin (2018-2025)
6.4.4 Octapharma Plasma Derived Medicine Product Portfolio
6.4.5 Octapharma Recent Developments/Updates
6.5 Kedrion
6.5.1 Kedrion Corporation Information
6.5.2 Kedrion Description and Business Overview
6.5.3 Kedrion Plasma Derived Medicine Sales, Revenue and Gross Margin (2018-2025)
6.5.4 Kedrion Plasma Derived Medicine Product Portfolio
6.5.5 Kedrion Recent Developments/Updates
6.6 LFB Group
6.6.1 LFB Group Corporation Information
6.6.2 LFB Group Description and Business Overview
6.6.3 LFB Group Plasma Derived Medicine Sales, Revenue and Gross Margin (2018-2025)
6.6.4 LFB Group Plasma Derived Medicine Product Portfolio
6.6.5 LFB Group Recent Developments/Updates
6.7 Biotest
6.6.1 Biotest Corporation Information
6.6.2 Biotest Description and Business Overview
6.6.3 Biotest Plasma Derived Medicine Sales, Revenue and Gross Margin (2018-2025)
6.4.4 Biotest Plasma Derived Medicine Product Portfolio
6.7.5 Biotest Recent Developments/Updates
6.8 BPL
6.8.1 BPL Corporation Information
6.8.2 BPL Description and Business Overview
6.8.3 BPL Plasma Derived Medicine Sales, Revenue and Gross Margin (2018-2025)
6.8.4 BPL Plasma Derived Medicine Product Portfolio
6.8.5 BPL Recent Developments/Updates
6.9 Shanghai RAAS
6.9.1 Shanghai RAAS Corporation Information
6.9.2 Shanghai RAAS Description and Business Overview
6.9.3 Shanghai RAAS Plasma Derived Medicine Sales, Revenue and Gross Margin (2018-2025)
6.9.4 Shanghai RAAS Plasma Derived Medicine Product Portfolio
6.9.5 Shanghai RAAS Recent Developments/Updates
6.10 China Biologic Products
6.10.1 China Biologic Products Corporation Information
6.10.2 China Biologic Products Description and Business Overview
6.10.3 China Biologic Products Plasma Derived Medicine Sales, Revenue and Gross Margin (2018-2025)
6.10.4 China Biologic Products Plasma Derived Medicine Product Portfolio
6.10.5 China Biologic Products Recent Developments/Updates
6.11 Hualan Biological Engineering Inc.
6.11.1 Hualan Biological Engineering Inc. Corporation Information
6.11.2 Hualan Biological Engineering Inc. Plasma Derived Medicine Description and Business Overview
6.11.3 Hualan Biological Engineering Inc. Plasma Derived Medicine Sales, Revenue and Gross Margin (2018-2025)
6.11.4 Hualan Biological Engineering Inc. Plasma Derived Medicine Product Portfolio
6.11.5 Hualan Biological Engineering Inc. Recent Developments/Updates
6.12 Beijing Tiantan Biological Products Corp
6.12.1 Beijing Tiantan Biological Products Corp Corporation Information
6.12.2 Beijing Tiantan Biological Products Corp Plasma Derived Medicine Description and Business Overview
6.12.3 Beijing Tiantan Biological Products Corp Plasma Derived Medicine Sales, Revenue and Gross Margin (2018-2025)
6.12.4 Beijing Tiantan Biological Products Corp Plasma Derived Medicine Product Portfolio
6.12.5 Beijing Tiantan Biological Products Corp Recent Developments/Updates
6.13 Pacific Shuanglin
6.13.1 Pacific Shuanglin Corporation Information
6.13.2 Pacific Shuanglin Plasma Derived Medicine Description and Business Overview
6.13.3 Pacific Shuanglin Plasma Derived Medicine Sales, Revenue and Gross Margin (2018-2025)
6.13.4 Pacific Shuanglin Plasma Derived Medicine Product Portfolio
6.13.5 Pacific Shuanglin Recent Developments/Updates
6.14 Boya Bio-Pharmaceutical
6.14.1 Boya Bio-Pharmaceutical Corporation Information
6.14.2 Boya Bio-Pharmaceutical Plasma Derived Medicine Description and Business Overview
6.14.3 Boya Bio-Pharmaceutical Plasma Derived Medicine Sales, Revenue and Gross Margin (2018-2025)
6.14.4 Boya Bio-Pharmaceutical Plasma Derived Medicine Product Portfolio
6.14.5 Boya Bio-Pharmaceutical Recent Developments/Updates
6.15 Paisi Feike Biology Pharmacy Co., Ltd.
6.15.1 Paisi Feike Biology Pharmacy Co., Ltd. Corporation Information
6.15.2 Paisi Feike Biology Pharmacy Co., Ltd. Plasma Derived Medicine Description and Business Overview
6.15.3 Paisi Feike Biology Pharmacy Co., Ltd. Plasma Derived Medicine Sales, Revenue and Gross Margin (2018-2025)
6.15.4 Paisi Feike Biology Pharmacy Co., Ltd. Plasma Derived Medicine Product Portfolio
6.15.5 Paisi Feike Biology Pharmacy Co., Ltd. Recent Developments/Updates
6.16 Xinjiang Deyuan Bioengineering
6.16.1 Xinjiang Deyuan Bioengineering Corporation Information
6.16.2 Xinjiang Deyuan Bioengineering Plasma Derived Medicine Description and Business Overview
6.16.3 Xinjiang Deyuan Bioengineering Plasma Derived Medicine Sales, Revenue and Gross Margin (2018-2025)
6.16.4 Xinjiang Deyuan Bioengineering Plasma Derived Medicine Product Portfolio
6.16.5 Xinjiang Deyuan Bioengineering Recent Developments/Updates
6.17 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
6.17.1 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. Corporation Information
6.17.2 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. Plasma Derived Medicine Description and Business Overview
6.17.3 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. Plasma Derived Medicine Sales, Revenue and Gross Margin (2018-2025)
6.17.4 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. Plasma Derived Medicine Product Portfolio
6.17.5 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. Recent Developments/Updates
6.18 Shenzhen Weiguang
6.18.1 Shenzhen Weiguang Corporation Information
6.18.2 Shenzhen Weiguang Plasma Derived Medicine Description and Business Overview
6.18.3 Shenzhen Weiguang Plasma Derived Medicine Sales, Revenue and Gross Margin (2018-2025)
6.18.4 Shenzhen Weiguang Plasma Derived Medicine Product Portfolio
6.18.5 Shenzhen Weiguang Recent Developments/Updates
6.19 Shanxi Kangbao
6.19.1 Shanxi Kangbao Corporation Information
6.19.2 Shanxi Kangbao Plasma Derived Medicine Description and Business Overview
6.19.3 Shanxi Kangbao Plasma Derived Medicine Sales, Revenue and Gross Margin (2018-2025)
6.19.4 Shanxi Kangbao Plasma Derived Medicine Product Portfolio
6.19.5 Shanxi Kangbao Recent Developments/Updates
6.20 Nanyue Biopharming Corporation Ltd
6.20.1 Nanyue Biopharming Corporation Ltd Corporation Information
6.20.2 Nanyue Biopharming Corporation Ltd Plasma Derived Medicine Description and Business Overview
6.20.3 Nanyue Biopharming Corporation Ltd Plasma Derived Medicine Sales, Revenue and Gross Margin (2018-2025)
6.20.4 Nanyue Biopharming Corporation Ltd Plasma Derived Medicine Product Portfolio
6.20.5 Nanyue Biopharming Corporation Ltd Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Plasma Derived Medicine Industry Chain Analysis
7.2 Plasma Derived Medicine Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Plasma Derived Medicine Production Mode & Process
7.4 Plasma Derived Medicine Sales and Marketing
7.4.1 Plasma Derived Medicine Sales Channels
7.4.2 Plasma Derived Medicine Distributors
7.5 Plasma Derived Medicine Customers
8 Plasma Derived Medicine Market Dynamics
8.1 Plasma Derived Medicine Industry Trends
8.2 Plasma Derived Medicine Market Drivers
8.3 Plasma Derived Medicine Market Challenges
8.4 Plasma Derived Medicine Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer